Introduction: Her2 / neu gene (HER2) is a member of the family of epidermal growth factor receptors (EGFR) encoding a 185 kd protein with tyrosine kinase activity. This gene is expressed in a variety of tissues such as kidney, skin, colon, ovary and mammary glands and mostly is found in plasma membrane. Following amplifying or increasing of HER2 transcription, carcinogenesis or deterioration of tumorigenicity has been observed in some cancers. Epigenetic mechanisms and chromatin modifications play a significant role in gene expression, transcriptional regulation, and cancer progression. Studies have shown that these changes can also affect the sequence of enhancers, short DNA motifs that serve as binding sites for specific transcription factors. Chromatin regions such as DNase I sensitive sites and histone modifications such as H3K4me1 and H3K27ac are used to predict possible enhancers. Active enhancers that express eRNAs (non-coding transcriptional RNAs derived from enhancers) have two H3K4me1 and H3K4me3 histone marks. A therapeutic approach that directly targets genomic changes can be valuable because it has no effect on healthy cells. The development of genome editing tools such as the CRISPR system could provide such an opportunity. In this study, we aimed to investigate the regulatory role of the GH17J039694 region as an enhancer, which we called HER2-En1 (HER2-Enhancer1) for short, located in the HER2 gene in the 17q12 region: 37850592-37853472 (GRCh37/hg19. 2009) with the help of bioinformatics studies and by using CRISPR/Cas9 technology for genetic manipulation. Materials and Methods: Genetic editing of this region was done for cis and trans studies in HER2+ and HER2-breast cancer cells. Bioinformatics studies were conducted in different cell lines with the help of databases such as GEO gene, ChIPAtlas and TCGA. The laboratory results showed the reduction of HER2 variants and expression changes of other studied genes. In general, according to bioinformatics and laboratory studies, it seems that this part of the HER2 gene can be considered as an integral regulatory region. Results: The results showed the decrease in the expression of the variants in the studied cell lines after 24 hours in cis and the expression changes of other studied genes in trans. Also, bioinformatic studies such as histone modifications (H3K27ac) showed the importance of HER2-En1 as a regulatory region. Conclusion: In general, according to bioinformatics and laboratory studies in the form of gene editing of the HER2-En1 region, it seems that this part of the HER2 sequence can be considered as an enhancer regulatory region.